SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care

TribeMD

SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care

By the Numbers

2.6M

Medical community members

140.000

Curated content pieces

60M+

Monthly pageviews

Content

See more
Complete revascularization reduces cardiovascular mortality in patients with acute myocardial infarction and multivessel coronary disease

Medical Affairs

Complete revascularization reduces cardiovascular mortality in patients with acute myocardial infarction and multivessel coronary disease

Myocardial revascularization in patients with acute myocardial infarction (AMI) and multivessel coronary artery disease remains a topic of ongoing debate, particularly regarding the benefit of treating only the culprit lesion versus performing complete revascularization. Previous clinical trials suggested a reduction in nonfatal events with a complete approach, but uncertainty persisted regarding its effect on cardiovascular and all-cause mortality. 

Cardiology

AHA®2025

November 14, 2025

3 min read

Dr. C. Michael Gibson and Dr. Shamir Mehta Review: Does Complete Revascularization Truly Reduce CV Death and MI?

Clinical Trial Results

Dr. C. Michael Gibson and Dr. Shamir Mehta Review: Does Complete Revascularization Truly Reduce CV Death and MI?

Live from AHA 2025, in this new SnackableHealth™, Dr. C. Michael Gibson sits down with Dr. Shamir Mehta to unpack the largest individual-patient-data meta-analysis ever conducted on complete versus culprit-only revascularization in ACS. By pooling six multicenter randomized trials, the Complete Revascularization Trialists’ Collaboration assembled a dataset of 8,836 patients, 910 cardiovascular deaths or new MIs, and 678 total deaths — finally providing the statistical power missing f

Cardiology

AHA®2025

November 13, 2025

4 min read

Beta-blocker therapy after myocardial infarction in patients with preserved ejection fraction

Medical Affairs

Beta-blocker therapy after myocardial infarction in patients with preserved ejection fraction

Beta-blocker therapy has long been considered the standard of care following acute myocardial infarction (MI). However, its role in patients with preserved ejection fraction (LVEF ≥50%) and without heart failure remains uncertain in modern practice, where most patients undergo early reperfusion and receive optimized medical therapy. The individual patient data meta-analysis

Cardiology

AHA®2025

November 13, 2025

3 min read

DECAF: Caffeinated Coffee Consumption After Cardioversion Reduces Atrial Fibrillation Recurrence

Medical Affairs

DECAF: Caffeinated Coffee Consumption After Cardioversion Reduces Atrial Fibrillation Recurrence

The DECAF randomized clinical trial evaluated the impact of daily caffeinated coffee consumption versus complete abstinence from coffee and caffeine for six months in patients with atrial fibrillation.  Atrial fibrillation is the most common sustained arrhythmia, associated with significant morbidity, and recurrence after cardioversion remains a clinical challenge, highlighti

Cardiology

AHA®2025

November 13, 2025

3 min read

Dr. Stephen Nicholls & Dr. C. Michael Gibson Discuss: SURPASS-CVOT

Clinical Trial Results

Dr. Stephen Nicholls & Dr. C. Michael Gibson Discuss: SURPASS-CVOT

Live from AHA 2025, Dr. Stephen Nicholls joins Dr. C. Michael Gibson in this SnackableHealth discussion to unpack the SURPASS-CVOT, the first cardiovascular outcomes trial (CVOT) testing tirzepatide — a dual GIP and GLP-1 receptor agonist — against an active comparator, dulaglutide, rather than placebo. This design sets a new benchmark: not whether the drug beats nothing, but whether it outperforms o

Cardiology

AHA®2025

November 12, 2025

4 min read

Dr. C. Michael Gibson & Dr. Ambreen Mohamed Discuss: FOOD-HF Randomized Trial

Clinical Trial Results

Dr. C. Michael Gibson & Dr. Ambreen Mohamed Discuss: FOOD-HF Randomized Trial

Fresh from AHA 2025, this SnackableHealth session probes a deceptively simple question with system-level ramifications: can “food as medicine” measurably improve short-term outcomes for recently hospitalized heart-failure patients? In FOOD-HF, investigators randomized 150 post-discharge patients into three groups: usual care; medically tailored meals (14 frozen, heart-healthy meals delivered weekly); or fresh produce + pantry staples with recipes to enable pa

Cardiology

AHA®2025

November 12, 2025

5 min read

Dr. William F. Fearon and Dr. C. Michael Gibson Discuss CAVIAR: Can Alirocumab Curb Cardiac Allograft Vasculopathy After Transplant?

Clinical Trial Results

Dr. William F. Fearon and Dr. C. Michael Gibson Discuss CAVIAR: Can Alirocumab Curb Cardiac Allograft Vasculopathy After Transplant?

In this SnackableHealth edition, Dr. William Fearon joins Dr. C. Michael Gibson live from AHA 2025 to unpack the CAVIAR trial — a NIH-funded, double-blind, randomized, placebo-controlled study testing whether adding alirocumab (a PCSK9 inhibitor) to standard therapy could slow the development of cardiac allograft vasculopathy (CAV) within the first year after heart transplantation. The trial enrolled 114 recipients, all place

Cardiology

AHA®2025

November 12, 2025

5 min read

Dr. Ambreen Mohamed and Dr. C. Michael Gibson Discuss: POLY-HF — A Polypill Strategy for Heart Failure with Reduced Ejection Fraction

Clinical Trial Results

Dr. Ambreen Mohamed and Dr. C. Michael Gibson Discuss: POLY-HF — A Polypill Strategy for Heart Failure with Reduced Ejection Fraction

In this episode of SnackableHealth™, Dr. C. Michael Gibson talks with Dr. Ambreen Mohamed about the POLY-HF trial, a NIH-funded, randomized, controlled study testing whether consolidating key heart failure therapies into a single capsule could improve adherence, uptake, and outcomes for patients with heart failure with reduced ejection fraction (HFrEF).The rationale is simple yet powerful: patients with HFrEF often face pill fatigue a

Oncology

AHA®2025

November 12, 2025

4 min read

Dr. Colin Berry and Dr. C. Michael Gibson Discuss: CorCMR – Non-Invasive Endotyping in Patients with Angina and No Obstructive Coronary Artery Disease: A Randomized, Controlled Trial

Clinical Trial Results

Dr. Colin Berry and Dr. C. Michael Gibson Discuss: CorCMR – Non-Invasive Endotyping in Patients with Angina and No Obstructive Coronary Artery Disease: A Randomized, Controlled Trial

Live from AHA 2025, Dr. C. Michael Gibson sits down with Dr. Colin Berry to discuss the CorCMR trial, a multicenter randomized study exploring how cardiac magnetic resonance (CMR) can redefine the management of patients with angina but no obstructive coronary artery disease. Despite the absence of major blockages, nearly half of patients undergoing angiography fall into this “diagnostic gray zone,” often left without clear therapeutic direction.In this trial, 273 patie

Cardiology

AHA®2025

November 12, 2025

Dr. C. Michael Gibson & Dr. Ginger Jiang on CELEBRATE: Pre-hospital Zalunfiban for STEMI in SnackableHealth

Clinical Trial Results

Dr. C. Michael Gibson & Dr. Ginger Jiang on CELEBRATE: Pre-hospital Zalunfiban for STEMI in SnackableHealth

In this SnackableHealth discussion, Dr. C. Michael Gibson and Dr. Ginger Jiang unpack CELEBRATE—a pre-hospital strategy using zalunfiban, a subcutaneous GP IIb/IIIa inhibitor, at first medical contact for STEMI. The north star is speed: if one-third to one-half of MI deaths happen before hospital arrival, pushing potent platelet inhibition upstream could be a game-changer. In 2,500 patients, early zalunfiban opened more arteries by cath-lab arrival and

Cardiology

AHA®2025

November 12, 2025

3 min read

See all
Preview

Highlights

FDA Approves New Antibody–Drug Conjugate for Non-Squamous Non–Small Cell Lung Cancer with c-Met Overexpression

Med.IQ

FDA Approves New Antibody–Drug Conjugate for Non-Squamous Non–Small Cell Lung Cancer with c-Met Overexpression

FDA Approves First Blood Test for Alzheimer’s Diagnosis

Med.IQ

FDA Approves First Blood Test for Alzheimer’s Diagnosis

Digital Remote Monitoring in People with Multiple Sclerosis

Med.IQ

Digital Remote Monitoring in People with Multiple Sclerosis

New 2025 ACC/AHA Multisociety Guideline Redefines ACS Management Strategies

Medical Affairs

New 2025 ACC/AHA Multisociety Guideline Redefines ACS Management Strategies

Artificial Intelligence in Clinical Practice: Ethical Dilemmas and Responsible Implementation Pathways

Medical Affairs

Artificial Intelligence in Clinical Practice: Ethical Dilemmas and Responsible Implementation Pathways

iPSC-Derived Dopaminergic Transplants Demonstrate Safety and Motor Improvement in Parkinson’s Disease.

Medical Affairs

iPSC-Derived Dopaminergic Transplants Demonstrate Safety and Motor Improvement in Parkinson’s Disease.

ESC®️ 2025 – BETAMI–DANBLOCK: Beta-blockers after infarction?

Medical Affairs

ESC®️ 2025 – BETAMI–DANBLOCK: Beta-blockers after infarction?

ESC®️ 2025 – Beyond Traditional Risk Factors: The Weight of Inflammation

Medical Affairs

ESC®️ 2025 – Beyond Traditional Risk Factors: The Weight of Inflammation

ESC®️ 2025 – Beta-blockers after infarction in slightly reduced ejection fraction

Medical Affairs

ESC®️ 2025 – Beta-blockers after infarction in slightly reduced ejection fraction

ESC®️ 2025 – Recent Trials in Heart Failure: New Perspectives and Challenges

Medical Affairs

ESC®️ 2025 – Recent Trials in Heart Failure: New Perspectives and Challenges

Cardiology

See more

Psychiatry

See more

Oncology

See more

Hematology

See more

Endocrinology

See more

Neurology

See more

Internal Medicine

See more

Channels

Browse our channels